SenesTech Q2 2024 Financial and Corporate Report FAQ

What is SenesTech’s main business?

SenesTech is the leader in fertility control to manage animal-pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control.

How did SenesTech perform financially in the first half of 2024?

SenesTech saw record revenue of $874,000 in the first half of 2024, a 62% increase compared to the first half of 2023, with improvement in margin percentages.

What contributed to SenesTech’s revenue growth in 2024?

The Evolve product line, launched this year, became SenesTech’s biggest-selling product line, contributing approximately 60% to this year’s revenue.

What are SenesTech’s near-term objectives?

SenesTech aims to achieve profitability by reducing cash burn through operational improvements and accelerating growth from initiatives like new product launches and distribution agreements.

What new products has SenesTech launched in 2024?

SenesTech launched Evolve for rats with key online retailers and a new Evolve Mouse solution, along with new product packing options.

Where can I find more information about SenesTech’s Q2 2024 results?

The full press release can be viewed at https://ibn.fm/RJNDj and more about the company at www.SenesTech.com.

Who is the CEO of SenesTech?

Joel Fruendt is the president and CEO of SenesTech.

What makes SenesTech’s products unique?

SenesTech’s products, like ContraPest and Evolve, are the only EPA-registered contraceptives for rats and mice, offering a humane, effective, and sustainable solution to pest management.

How does SenesTech contribute to integrated pest-management programs?

ContraPest and Evolve fit seamlessly into all integrated pest-management programs, significantly improving the overall goal of effective pest management.

Where can investors find the latest news about SenesTech?

The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES.